L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH
Status:
Not yet recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
The efficacy and safety of L-DEP (PEG-aspargase, liposomal doxorubicin, etoposide, and
methylprednisolone) regimen combined with PD-1 Antibody an induction therapy for Epstein-Barr
virus (EBV)-positive lymphoma-associated hemophagocytic lymphohistiocytosis.